Shenzhen Children's Hospital to Transfer Four Stem Cell Exosome Engineering Technologies for RMB 400,000
Recently, Shenzhen Children's Hospital released a public notice on the transformation of scientific and technological achievements, proposing to transfer the hospital-heldFour Core Patents in the Fields of Biopharmaceuticals and Medical AestheticsBundle transfer, with the transferee beingShenzhen Stem Cell Science Co., Ltd., the transfer fee is a fixed fee400,000 yuan. This patent portfolio comprises one utility model patent and three invention patents, focusing onEngineering and Large-Scale Preparation of Mesenchymal Stem Cells (MSCs) and Their Small Extracellular Vesicles (sEVs).
This achievement marks a significant breakthrough for the hospital in the field of non-cellular stem cell therapy. The team has developedA Full-Chain Technical System Spanning from Source Cell Quality Control to Downstream Engineering Applications:By leveraging the proprietary “Hybrid Dynamic Culture” technology, we have successfully prepared mesenchymal stem cell-derived exosomes with high functional uniformity and minimal batch-to-batch variation, thereby overcoming the challenge of “heterogeneity” in the industrial-scale production of exosomes. Meanwhile, integratingEndogenous Loading and Click Chemistry Modification Technology, the team has developed a solution targetingOptic Nerve Damage (Glaucoma), Chronic Respiratory Diseases, and Skin Repairtargeted delivery strategy.
Compared with traditional stem cell therapies or conventional exosome products, this series of technologies not only addresses the administration challenges of poor solubility and low bioavailability associated with traditional Chinese medicine monomers (such as berberine), but also enables precise targeted therapy for fundus and pulmonary lesions through non-invasive or minimally invasive delivery methods (such as nasal drops and nebulization), thereby significantly enhancing the feasibility of clinical translation and therapeutic efficacy.
Despite the immense potential of MSCs and their sEVs in regenerative medicine and immunomodulation, their transition from the laboratory to clinical application and industrial-scale production has long facedInconsistent preparation standards, difficulties in targeted delivery, and limited sources of raw materialsThree Core Bottlenecks.
First, the "heterogeneity" of stem cells makes it difficult to standardize manufacturing processes, thereby limiting the consistency evaluation of drug products.Mesenchymal stem cells (MSCs) from different donor sources are often influenced by genetic background, age, and epigenetics, resulting in significant inter-individual variability. This variability leads to substantial fluctuations in the composition (protein and nucleic acid cargo) and function (anti-inflammatory and reparative capacity) of exosomes produced across different batches. The current cultivation model relying on a single individual source fails to yield universal exosomes with consistent quality and stable efficacy, representing the greatest obstacle to their industrial-scale mass production and clinical efficacy evaluation.
Secondly, the presence of physiological barriers poses a challenge for ophthalmic and respiratory diseases, characterized by "difficult drug delivery and short retention time."In the treatment of optic nerve injuries (such as glaucoma), the blood-ocular barrier and the low permeability of the cornea and conjunctiva hinder traditional eye drops from effectively delivering drugs to retinal ganglion cells; while intravitreal injections are effective, they are associated with high invasiveness and risk of infection. Similarly, in the treatment of respiratory diseases, traditional single-agent drugs (such as berberine, which has potent anti-inflammatory effects) are limited by poor water solubility, low bioavailability, and the obstruction of the pulmonary mucus barrier, making it difficult for them to reach deep lesion sites via oral administration or conventional nebulization, and they are prone to causing toxic side effects. How to overcome these physiological barriers to achieve non-invasive or minimally invasive precise delivery is an urgent clinical challenge that needs to be addressed.
Furthermore, the acquisition of bioactive raw materials has long been constrained by the dual burdens of ethical concerns and sourcing limitations.In the fields of medical aesthetics and tissue repair, traditional leukocyte extracts primarily rely on isolation from neonatal umbilical cord blood or adult peripheral blood. This approach is not only constrained by stringent regulations on blood products and ethical controversies but also faces challenges in large-scale mass production. More critically, components directly isolated from blood often contain pro-inflammatory cells such as neutrophils, which may introduce skin-irritating substances into the extract. Consequently, these extracts fail to meet the rigorous purity and safety standards required for high-end medical aesthetic applications.
These industry pain points have relegated many promising therapeutic strategies to the awkward predicament of being “theoretically effective but practically ineffective.” Therefore, developing a comprehensive technical solution that addresses cellular source heterogeneity while enabling high-efficiency drug loading and targeted trans-barrier delivery has become the key to breaking this deadlock.
This transfer project is based onStem Cell Exosome Engineering Technologycentered on this, it has achieved technological leaps across three dimensions—underlying manufacturing processes, drug delivery systems, and the development of novel biomaterials—thereby establishing a highly competitive core advantage system:
Pioneering the “Multi-Donor Mixed 3D Dynamic Culture” Technology
To address the industry-wide challenge of significant batch-to-batch variability in stem cell-derived exosomes, the team has developed a technology for preparing mesenchymal stem cell exosomes with functional uniformity. This technology abandons the traditional single-donor culture model and innovatively adopts“Multi-donor Zonal Static Culture + Hybrid 3D Dynamic Microcarrier Culture” StrategyBy leveraging the beneficial competition and synergistic effects among cells from different donors, combined with industrial-scale 3D suspension culture processes, we have successfully prepared universal exosomes with highly consistent protein composition and purity exceeding 98%. This breakthrough not only eliminates quality fluctuations caused by donor heterogeneity but also significantly enhances the anti-inflammatory and immunomodulatory functions of exosomes compared to those derived from a single donor, laying a solid foundation for the standardization of chemical manufacturing controls (CMC) for exosome-based therapeutics.
Achieving Dual Precision Delivery to the “Nose-Brain” Axis and “Deep Lung” Regions
In the field of drug delivery, the team leveraged the natural nanocarrier properties of exosomes, combined with engineered modifications, to address the challenges of administering drugs for refractory diseases:
Ophthalmology (Innovation in Intranasal Drug Delivery):For the treatment of optic nerve injury, the team has developedCholera Toxin B Subunit (CTB)-Modified Engineered ExosomesBy leveraging click chemistry and lipid insertion, CTB was precisely modified onto the exosome surface. CTB can specifically recognize GM1 receptors on the surface of nerve cells, enabling the drug to bypass the blood-retinal barrier via the nose-to-brain pathway through nasal drops, thereby directly targeting and repairing damaged retinal ganglion cells. This novel strategy of “intranasal administration for fundus therapy” fundamentally transforms the high-risk status quo associated with intraocular injections.
Respiratory Field (Endogenous Loading):To address the poor solubility and low bioavailability of traditional berberine, the team inventedEndogenous Loading Technology for Engineered ExosomesDuring 3D stem cell culture, drugs are directly introduced and “naturally encapsulated” into exosomes by leveraging the cells’ own biosynthetic machinery. This formulation not only masks the bitter taste of the drug but also utilizes the phospholipid bilayer structure of exosomes to penetrate the pulmonary mucus barrier, enabling efficient treatment of bronchopulmonary dysplasia and asthma via nebulized inhalation, thereby achieving a nanoscale upgrade of traditional Chinese medicine monomers.
Pioneering a New Pathway for “In Vitro Induction”
In the realm of raw materials for medical aesthetics, the team has developedPreparation Technology for Inducible Leukocyte ExtractsThis technology takes a novel approach, moving away from blood extraction to instead utilize mesenchymal stem cells that are directionally induced to differentiate into functional dendritic cells in vitro, followed by lysis to obtain active ingredients. This method not only completely circumvents the legal and ethical risks associated with blood products, enabling unlimited, standardized production of raw materials, but also yields products rich in anti-aging, whitening, and repair factors while removing impurities that cause skin inflammation. It provides a safer, purer, and more compliant “leukocyte-like” core ingredient for high-end medical aesthetic skincare products.
As the global exosome industry experiences explosive growth, this emerging sector is shifting from a “research fervor” to an “industrial boom.” The four patented technologies involved in this transfer not only strategically position themselves at the core preparation stage of regenerative medicine, but also establish highly differentiated competitive barriers in three high-growth markets: ophthalmic drugs, respiratory inhalation formulations, and high-end medical aesthetics raw materials.
Ophthalmic Drug Delivery Opens Up a New Blue Ocean for “Home-Based Treatment”
The global population of patients with glaucoma and optic nerve damage is substantial, yet existing clinical treatments rely heavily on frequent hospital visits and invasive procedures. This project has developedCTB-Modified Exosome Nasal Drops, it not only holds promise for replacing high-risk intravitreal injections but also extends the treatment setting from the operating room to patients’ homes, significantly improving patient adherence. In the current landscape where the ophthalmic pharmaceutical market is transitioning toward non-invasive and precision therapies, this “intranasal drug delivery” technology possesses substantial potential for commercial translation.
Modernization of Traditional Chinese Medicine Seizes the High Ground in Managing Chronic Respiratory Diseases
For respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and bronchopulmonary dysplasia in neonates, inhaled formulations are widely recognized as the “gold standard” route of administration. This project combines a traditional Chinese medicine monomer (berberine) with stem cell-derived exosomes to developNovel Nebulized Inhalation Agent, it not only resolves the compliance challenges associated with the bitter taste of traditional Chinese medicine (TCM) and children’s refusal to take medication, but also achieves targeted delivery of the drug to the deep lung tissues. This represents a successful exploration in the modernization of TCM and introduces a blockbuster product with both anti-inflammatory and reparative functions to the market for chronic respiratory disease management.
Reshaping the Supply Chain of Raw Materials for Medical Aesthetics
In the hundred-billion-yuan market for medical aesthetics and functional skincare, consumers are becoming increasingly stringent in their demands for ingredient safety and efficacy. The project introducesInducible Leukocyte Extract, providing the market with a standardized, mass-producible, high-purity bioactive ingredient. In today’s climate, where concepts such as “exosome-based beauty” and “cellular-level repair” are highly sought after, this compliant raw material is poised to rapidly penetrate the supply chain for high-end skincare products.
Platform-Enabled Technology Empowers Industrialization by Bridging Critical Bottlenecks
More importantly, the project includesScalable Manufacturing Technology for Functionally Homogeneous Exosomes, it essentially provides a universal foundation for industrialized production. It addresses the most costly and challenging aspects of exosome drug development: manufacturing processes and quality control. For the transferee, Shenzhen Side Mother Cell Science Co., Ltd., this not only means acquiring three specific potential products but also mastering the platform capability to rapidly incubate additional exosome pipelines.
In summary, the RMB 400,000 patent transfer effectively completes a full-industry-chain layout spanning from upstream preparation processes to downstream multi-scenario applications. It not only holds promise for delivering revolutionary therapeutic solutions for clinically refractory diseases but also injects robust innovative momentum into the company’s competitive edge in the dual tracks of biopharmaceuticals and medical aesthetics.